Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial
Nephrology Dialysis Transplantation · 04.02.2025 · 40 (2) · 308-319
DOI: 10.1093/ndt/gfae132 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 11.06.2024. Verfasst von Hiddo J L Heerspink und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy and Pharmacology, University of Groningen, Groningen, The Netherlands. Hauptthemen laut MEDLINE: Mineralocorticoid Receptor Antagonists, Naphthyridines, Renal Insufficiency, Chronic, Standard of Care. Die Arbeit wurde bisher 96-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bayer.
Abstract (Originalsprache)
Background
Finerenone, a non-steroidal mineralocorticoid receptor antagonist, improved kidney and cardiovascular outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes in two phase 3 outcome trials. The Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) study investigates the effect of finerenone in adults with CKD without diabetes.
Methods
FIND-CKD (NCT05047263 and EU CT 2023-506897-11-00) is a randomized, double-blind, placebo-controlled phase 3 trial in patients with CKD of non-diabetic aetiology. Adults with a urinary albumin:creatinine ratio (UACR) ≥200–≤3500 mg/g and an estimated glomerular filtration rate (eGFR) ≥25–<90 ml/min/1.73 m2 receiving a maximum tolerated dose of a renin–angiotensin system inhibitor were randomized 1:1 to once-daily placebo or finerenone 10 or 20 mg depending on eGFR >60 or <60 ml/min/1.73 m2. The primary efficacy outcome is total eGFR slope, defined as the mean annual rate of change in eGFR from baseline to month 32. Secondary efficacy outcomes include a combined cardiorenal composite outcome comprising time to kidney failure, sustained ≥57% decrease in eGFR, hospitalization for heart failure or cardiovascular death, as well as separate kidney and cardiovascular composite outcomes. Adverse events are recorded to assess tolerability and safety.
Results
Across 24 countries, 3231 patients were screened and 1584 were randomized to study treatment. The most common causes of CKD were chronic glomerulonephritis (57.0%) and hypertensive/ischaemic nephropathy (29.0%). Immunoglobulin A nephropathy was the most common glomerulonephritis (26.3% of the total population). At baseline, mean eGFR and median UACR were 46.7 ml/min/1.73 m2 and 818.9 mg/g, respectively. Diuretics were used by 282 participants (17.8%), statins by 851 (53.7%) and calcium channel blockers by 794 (50.1%). Sodium–glucose co-transporter 2 (SGLT2) inhibitors were used in 16.9% of patients; these individuals had a similar mean eGFR (45.6 versus 46.8 ml/min/1.73 m2) and a slightly higher median UACR (871.9 versus 808.3 mg/g) compared with those not using SGLT2 inhibitors at baseline.
Conclusions
FIND-CKD is the first phase 3 trial of finerenone in patients with CKD of non-diabetic aetiology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacy and Pharmacology, University of Groningen, Groningen, The Netherlands.
- Division of Nephrology, Department of Medicine, Indiana University School of Medicine and RL Roudebush VA Medical Center, Indianapolis, IN, USA.
- Department of Medicine, AHA Comprehensive Hypertension Center, University of Chicago Medicine, Chicago, IL, USA.
- Department of Medicine, Division of Nephrology, University Health Network, Toronto, ON, Canada.
- National Heart Centre Singapore, Singapore, Singapore.
- Duke-National University of Singapore Medical School, Singapore, Singapore.
ORCID-Profile: Hiddo J L Heerspink, Brendon L Neuen, Pantelis A Sarafidis, Katherine R Tuttle, Christoph Wanner, Peter Kolkhof
Förderung
- Bayer
Zitieren
APA
Heerspink, H. J. L., Agarwal, R., Bakris, G. L., Cherney, D. Z. I., Lam, C. S. P., Neuen, B. L., Sarafidis, P. A., Tuttle, K. R., Wanner, C., Brinker, M. D., Dizayee, S., Kolkhof, P., Schloemer, P., Vesterinen, P., Perkovic, V., & FIND-CKD investigators (2025). Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial. Nephrology Dialysis Transplantation, 40(2), 308-319. https://doi.org/10.1093/ndt/gfae132
Vancouver
Heerspink HJL, Agarwal R, Bakris GL, Cherney DZI, Lam CSP, Neuen BL, et al. Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial. Nephrology Dialysis Transplantation. 2025;40(2):308-319. doi:10.1093/ndt/gfae132
BibTeX
@article{Heerspink2025,
author = {Heerspink, Hiddo J L and Agarwal, Rajiv and Bakris, George L and Cherney, David Z I and Lam, Carolyn S P and Neuen, Brendon L and Sarafidis, Pantelis A and Tuttle, Katherine R and Wanner, Christoph and Brinker, Meike D and Dizayee, Sara and Kolkhof, Peter and Schloemer, Patrick and Vesterinen, Paula and Perkovic, Vlado and FIND-CKD investigators, FIND-CKD investigators},
title = {Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial},
journal = {Nephrology Dialysis Transplantation},
year = {2025},
volume = {40},
number = {2},
pages = {308--319},
doi = {10.1093/ndt/gfae132}
}
EUVIMED